Skip to main content
Evidence Snapshot

Carbonic anhydrase 7

CHEMBL2326 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:51Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2326
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Carbonic anhydrase 7 as ChEMBL target CHEMBL2326, mapped to UniProt P43166. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Carbonic anhydrase 7
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2326
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P43166
Carbonic anhydrase 7
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Carbonic anhydrase 7 matters

As of 2026-09-13

Carbonic anhydrase 7 is reviewed as Carbonic anhydrase 7 (UniProt P43166); Carbonic anhydrase 7 shows approved-linked disease relevance led by glaucoma. 4 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 31 approved drugs, 1876 compounds, and 180 assays, with lead potency reaching pChEMBL 11.0.

Disease context
glaucoma

Carbonic anhydrase 7 shows approved-linked disease relevance led by glaucoma. 4 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include METHAZOLAMIDE.

Start review with glaucoma because it currently carries approved-linked support. Linked drugs include METHAZOLAMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 31 approved drugs, 1876 compounds, and 180 assays for this target. The dominant activity type is KI. CHEMBL4442511 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL4442511 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
31 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Carbonic anhydrase 7 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P43166, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why glaucoma is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1876
Total Compounds
180
Total Assays
31
Approved Drugs
IC50: 6.0, KI: 1643.0, KD: 627.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4442511
 11.0 Kd —
No preferred name
CHEMBL4444201
 11.0 Kd —
No preferred name
CHEMBL4450306
 11.0 Kd —
No preferred name
CHEMBL4456084
 11.0 Kd —
No preferred name
CHEMBL4515586
 11.0 Kd —

Approved Drugs

Structure Compound First Approval
NILOTINIB
CHEMBL255863
 2007
IMATINIB
CHEMBL941
 2001
ZONISAMIDE
CHEMBL750
 2000
BRINZOLAMIDE
CHEMBL220491
 1998
TOPIRAMATE
CHEMBL220492
 1996
DORZOLAMIDE
CHEMBL218490
 1994
FAMOTIDINE
CHEMBL902
 1986
SULFANILAMIDE
CHEMBL21
 1985
INDAPAMIDE
CHEMBL406
 1983
ETHOXZOLAMIDE
CHEMBL18
 1982
METOLAZONE
CHEMBL878
 1973
MAFENIDE
CHEMBL419
 1969
FUROSEMIDE
CHEMBL35
 1966
CHLORTHALIDONE
CHEMBL1055
 1960
TRICHLORMETHIAZIDE
CHEMBL1054
 1960
METHAZOLAMIDE
CHEMBL19
 1959
DICHLORPHENAMIDE
CHEMBL17
 1958
ACETAZOLAMIDE
CHEMBL20
 1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:51Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2326